RS
ABVX

R Squared’s Abivax ABVX Stock Holding History

R Squared’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,950
Closed -$36.2K – 297
2024
Q4 		$36.2K Buy
+4,950
New +$45.6K 0.04% 630

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

R Squared's ABVX Position: Q1 2025 in Review

R Squared sold out of Abivax (ABVX) in Q1 2025, closing a stake of 4,950 shares — an estimated $36.2K sold.

R Squared first reported a position in ABVX in Q4 2024 and held it in 1 quarter. The position peaked at $36.2K in Q4 2024. 46 funds tracked by Wall St. Rank hold ABVX as of Q1 2025.

  • R Squared reported no remaining Abivax position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 4,950 Abivax shares in Q1 2025, an estimated $36.2K.
  • R Squared first reported a position in Abivax in Q4 2024 and held it in 1 quarter.
  • R Squared's Abivax position peaked at $36.2K in Q4 2024.
  • 46 funds tracked by Wall St. Rank held Abivax as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.